Pamisell has ranked among the top searched stocks for 7 days in the past month.
As of 12:30 PM on the 2nd, Pamisell is trading at 20,550 KRW, down 1.91% from the previous day. This represents an 11.99% decrease compared to November 18. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreigners have a provisional net purchase of 28,915 shares of Pamisell, and institutions have a net purchase of 3,000 shares. Over the past 5 days, individual investors have net purchased 318,705 shares, while foreigners and institutions have net sold 296,323 shares and 118 shares, respectively.
On December 1, Pamisell became an issue in the market with the headline "Rising start backed by Moderna, etc."
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
